OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 175.87 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 41.86K shares, a 69.20% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 134.00K shares, a 18.47% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 169.18K shares, a 29.55% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 122.97K shares, a 388.20% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 541.17K shares, a 61.16% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 335.79K shares, a 77.75% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.51M shares, a 168.90% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 561.36K shares, a 451.61% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 175.87K shares 10-Q · filed 2026-08-10 | 345.05K shares derived: sum of 3 quarters · filed 2026-08-10 | 468.02K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 134.00K shares 10-Q · filed 2026-05-12 | 303.18K shares derived: sum of 2 quarters · filed 2026-05-12 | 426.15K shares derived: sum of 3 quarters · filed 2026-05-12 | 562.07K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 169.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 292.15K shares derived: sum of 2 quarters · filed 2026-03-16 | 428.06K shares derived: sum of 3 quarters · filed 2026-03-16 | 541.17K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 122.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 258.88K shares derived: sum of 2 quarters · filed 2025-11-10 | 371.99K shares 10-Q · filed 2025-11-10 | 502.58K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 135.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 249.02K shares 10-Q · filed 2025-08-11 | 379.61K shares derived: sum of 3 quarters · filed 2025-08-11 | 404.80K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 113.11K shares 10-Q · filed 2025-05-13 | 243.70K shares derived: sum of 2 quarters · filed 2025-05-13 | 268.89K shares derived: sum of 3 quarters · filed 2025-05-13 | 342.89K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 130.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 155.78K shares derived: sum of 2 quarters · filed 2025-03-18 | 229.78K shares derived: sum of 3 quarters · filed 2025-03-18 | 335.79K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 25.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 99.19K shares derived: sum of 2 quarters · filed 2024-11-12 | 205.20K shares 10-Q · filed 2024-11-12 | 650.38K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 74.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 180.01K shares 10-Q · filed 2024-08-06 | 625.20K shares derived: sum of 3 quarters · filed 2024-08-06 | 830.07K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 106.02K shares 10-Q · filed 2024-05-08 | 551.20K shares derived: sum of 2 quarters · filed 2024-05-08 | 756.07K shares derived: sum of 3 quarters · filed 2024-05-08 | 1.18M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 445.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 650.05K shares derived: sum of 2 quarters · filed 2024-03-11 | 1.07M shares derived: sum of 3 quarters · filed 2024-03-11 | 1.51M shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 204.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 627.48K shares derived: sum of 2 quarters · filed 2023-11-07 | 1.06M shares 10-Q · filed 2023-11-07 | 1.16M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 422.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 859.45K shares 10-Q · filed 2023-08-08 | 959.05K shares derived: sum of 3 quarters · filed 2023-08-08 | 1.19M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 436.84K shares 10-Q · filed 2023-05-09 | 536.44K shares derived: sum of 2 quarters · filed 2023-05-09 | 770.70K shares derived: sum of 3 quarters · filed 2023-05-09 | 957.62K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 99.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 333.87K shares derived: sum of 2 quarters · filed 2023-03-09 | 520.78K shares derived: sum of 3 quarters · filed 2023-03-09 | 561.36K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 234.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 421.18K shares derived: sum of 2 quarters · filed 2022-11-08 | 461.76K shares 10-Q · filed 2022-11-08 | 475.86K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 186.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 227.50K shares 10-Q · filed 2022-08-09 | 241.60K shares derived: sum of 3 quarters · filed 2022-08-09 | 322.57K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 40.58K shares 10-Q · filed 2022-05-09 | 54.68K shares derived: sum of 2 quarters · filed 2022-05-09 | 135.66K shares derived: sum of 3 quarters · filed 2022-05-09 | |
| 2021-12-31 | 14.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 95.08K shares derived: sum of 2 quarters · filed 2022-02-28 | 101.77K shares 10-K · filed 2022-02-28 | |
| 2021-09-30 | 80.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 87.67K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 6.69K shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |